1. Signaling Pathways
  2. Immunology/Inflammation
  3. NTPDase
  4. NTPDase2 Isoform

NTPDase2

NTPDase2 is a plasma-membrane ecto-ATPase that hydrolyzes extracellular ATP to ADP and thereby shapes purinergic signaling[1]. Mechanistically, NTPDase2 differs from NTPDase1 because it preferentially hydrolyzes nucleoside triphosphates and permits ADP accumulation, whereas NTPDase1 limits ADP accumulation more efficiently[2][3]. In adult mouse neurogenic niches, NTPDase2 scavenges mitogenic extracellular nucleoside triphosphates and controls neural progenitor cell proliferation[4]. In taste buds, Entpd2 deletion causes extracellular ATP accumulation, receptor desensitization, and reduced taste-nerve transmission[5]. In liver models, portal fibroblast NTPDase2 inhibits bile duct epithelial proliferation through blockade of P2Y activation, while biliary cirrhosis selectively down-regulates NTPDase2 expression[6][7]. For experimental applications, ARL 67156 is not an effective inhibitor of NTPDase2, so NTPDase2 studies require isoform-aware enzymatic assays rather than assuming broad ecto-ATPase inhibition[8].

NTPDase2 Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-D0976
    NF279
    Inhibitor 98.5%
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
  • HY-120566
    PSB-16131
    Inhibitor 99.94%
    PSB-16131 is a potent inhibitor of human NTPDase2, showing non-competitive inhibition with an IC50 of 539 nM. PSB-16131 can be used in the study of inflammation, neurodegenerative diseases and cancer.